Thursday, June 11

Browsing: Epcoritamab

Support

Fixed-Duration Epcoritamab Combo Shows Superiority in Follicular Lymphoma

By NewsCancerJune 11, 20260

The addition of fixed-duration epcoritamab-bysp (Epkinly) to lenalidomide (Revlimid) and rituximab (Rituxan) exhibited superior outcomes vs lenalidomide/rituximab alone across key…

► Necessary Cookies Always Active

Necessary cookies enable essential site features like secure log-ins and consent preference adjustments. They do not store personal data.

► Functional Cookies Remark

Functional cookies support features like content sharing on social media, collecting feedback, and enabling third-party tools.

► Analytical Cookies Remark

Analytical cookies track visitor interactions, providing insights on metrics like visitor count, bounce rate, and traffic sources.

► Advertisement Cookies Remark

Advertisement cookies deliver personalized ads based on your previous visits and analyze the effectiveness of ad campaigns.

What's Hot

Boy whose cancer returned two weeks after remission gets new hope from trial

CFTR-driven immune microenvironment reprogramming synergizes with anti-PD-L1 antibody in hepatocellular carcinoma

74 Real-World Study Characterizing Patient Characteristics, Treatments, and Unmet Need in IO-Ineligible Patients With Metastatic Triple-Negative Breast Cancer

Browsing: Epcoritamab

Fixed-Duration Epcoritamab Combo Shows Superiority in Follicular Lymphoma

Boy whose cancer returned two weeks after remission gets new hope from trial

CFTR-driven immune microenvironment reprogramming synergizes with anti-PD-L1 antibody in hepatocellular carcinoma

74 Real-World Study Characterizing Patient Characteristics, Treatments, and Unmet Need in IO-Ineligible Patients With Metastatic Triple-Negative Breast Cancer

Is Any Alcohol Good for You? Health Risks of Alcohol| U.S. News

Boy whose cancer returned two weeks after remission gets new hope from trial

CFTR-driven immune microenvironment reprogramming synergizes with anti-PD-L1 antibody in hepatocellular carcinoma

74 Real-World Study Characterizing Patient Characteristics, Treatments, and Unmet Need in IO-Ineligible Patients With Metastatic Triple-Negative Breast Cancer

Is Any Alcohol Good for You? Health Risks of Alcohol| U.S. News

Latest Post

Boy whose cancer returned two weeks after remission gets new hope from trial

CFTR-driven immune microenvironment reprogramming synergizes with anti-PD-L1 antibody in hepatocellular carcinoma

74 Real-World Study Characterizing Patient Characteristics, Treatments, and Unmet Need in IO-Ineligible Patients With Metastatic Triple-Negative Breast Cancer

Subscribe to Updates

What's Hot

Browsing: Epcoritamab